List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 10 studies with search of: octanoic acid
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
Condition: Essential Tremor
Intervention: Drug: Octanoic Acid
2 Completed Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Drug: Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, USP
3 Completed Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, USP
4 Completed Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
5 Completed Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Conditions: Immunologic Deficiency Syndrome;   Agammaglobulinemia;   Severe Combined Immunodeficiency;   Wiskott-Aldrich Syndrome;   Common Variable Immunodeficiency
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Dextrose, 5% in Water
6 Completed Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, USP
7 Completed A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
Condition: Immunologic Deficiency Syndrome
Intervention: Drug: Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
8 Recruiting Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance.
Conditions: Pharmacodynamics;   Ill
Interventions: Drug: GSK962040;   Drug: Placebo
9 Recruiting The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis.
Conditions: Diabetic Gastroparesis;   Gastroparesis
Intervention: Drug: GSK962040 or Placebo
10 Recruiting Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Intervention: Dietary Supplement: Medium chain fatty acid (Octanoic and Decanoic acid)

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services